Securities Code: 002370 Securities Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-032
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.
Announcement on Using Idle Own Funds for Cash Management
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Asia-Pacific Pharmaceutical") held its Eighth Board of Directors' Twelfth Meeting on April 23, 2026, and deliberated and passed the "Proposal on Using Idle Own Funds for Cash Management." The Company agreed to use no more than RMB 50,000 million (inclusive) of idle own funds for cash management, provided that normal operations are not affected and risks are effectively controlled. The period of use is within 12 months from the date of deliberation and approval by the 2025 Annual Shareholders' Meeting. Funds can be rolled over within the aforementioned amount and period. The relevant matters are hereby announced as follows:
I. Basic Situation of Using Idle Own Funds for Cash Management
(I) Investment Purpose To improve fund utilization efficiency, and under the premise of ensuring the Company's daily operating fund needs and fund safety, to reasonably utilize idle own funds for cash management, increase fund returns, better achieve the preservation and appreciation of company assets, and maximize the benefits for the Company and shareholders.